GoldenGolden
Advanced Search
Celladon

Celladon

Celladon is a biotechnology company that focuses in the development of molecular therapies to treat heart failure.

Celladon is a biotechnology company that applies its leadership position in the area of cardiovascular gene therapy to create novel therapies for diseases with unmet medical needs.

Timeline

November 2015
Celladon raises a $39,500,000 venture round from HBM Healthcare Investments AG, InterWest Partners, Perceptive Advisors, RA Capital Management, Sabby Capital and Vivo Capital.
October 2013
Celladon raises a $1,100,000 venture round.
May 2012
Celladon raises a $10,000,000 venture round from Life Sciences Partners and MPM Capital.
February 2012
Celladon raises a $43,000,000 venture round from GBS Venture Partners, Novartis Venture Fund and Venrock.
December 2011
Celladon raises a $500,000 venture round.
September 2011
Celladon raises a $250,000 venture round.
October 2010
Celladon raises a $2,500,000 venture round.
December 2009
Celladon raises a $3,500,000 venture round.
November 1, 2009
Celladon raises a $21,800,000 series C round from Venrock.
November 2009
Celladon raises a $21,800,000 series C round from Enterprise Partners, Johnson & Johnson Development Corporation and Venrock.
Page 1 of 2

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.